Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
University of Washington to run prospective ibogaine study; committee hears update on psilocybin safety work
Summary
University of Washington researchers reported progress on state‑funded studies of psilocybin and ibogaine. The committee heard staff briefings on Senate Bill 5,204 (an Ibogaine‑assisted therapy study) and a status update from UW’s Center for Novel Therapeutics and Addiction Psychiatry.
Committee members received a work‑session update from Dr. Nathan Sackett, director of the University of Washington Center for Novel Therapeutics and Addiction Psychiatry (NTAP), on two state‑funded research projects and then heard a staff briefing on Senate Bill 5,204, which would require a prospective randomized cohort study of ibogaine‑assisted therapy for opioid use disorder.
Dr. Sackett said NTAP’s federally approved psilocybin ‘‘high risk’’ safety study is at its midpoint. The study targets veterans and first responders with co‑occurring post‑traumatic stress disorder and alcohol use disorder and will enroll about 40 participants; Dr. Sackett reported Institutional Review Board (IRB) and FDA approvals, completed therapist…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
